--- title: "Acumen Pharmaceuticals IncQ) expected to post a loss of 52 cents a share - Earnings Preview" description: "Acumen Pharmaceuticals IncQ) is expected to report a loss of 52 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts have a strong buy rating on the stoc" type: "news" locale: "en" url: "https://longbridge.com/en/news/252265648.md" published_at: "2025-08-08T15:32:05.000Z" --- # Acumen Pharmaceuticals IncQ) expected to post a loss of 52 cents a share - Earnings Preview > Acumen Pharmaceuticals IncQ) is expected to report a loss of 52 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts have a strong buy rating on the stock, with a median 12-month price target of $10.00, significantly above its last closing price of $1.42. The mean earnings estimate has risen by 15.3% in the last three months. Previous quarterly performances show a trend of missed estimates. - Acumen Pharmaceuticals Inc (ABOS.OQ) (ABOS.O) is expected to show no change in quarterly revenue when it reports results on August 12 for the period ending June 30 2025 - ​LSEG’s mean analyst estimate for Acumen Pharmaceuticals Inc is for a loss of 52 cents per share. - The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 6 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” - The mean earnings estimate of analysts had risen by about 15.3% in the last three months. ​ - Wall Street’s median 12-month price target for Acumen Pharmaceuticals Inc is $10.00, about 85.8% above its last closing price of $1.42 Previous quarterly performance (using preferred earnings measure in US dollars). ​ ### QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI ### ENDING ARTESTIMAT ESTIMATE MET, SE % ### E® MISSED Mar. 31 2025 -0.41 -0.45 -0.48 Missed -5.7 Dec. 31 2025 -0.48 -0.62 Missed -29.2 Sep. 30 2024 -0.41 -0.36 -0.50 Missed -37​ Jun. 30 2024 -0.28 -0.28 -0.34 Missed -21.4 ​​Mar. -0.26 -0.26 -0.25 Beat 3.8 31 2024 Dec. 31 2023 -0.30 -0.26 -0.28 Missed -7.7​ Sep. 30 2023 -0.27 -0.27 -0.24 Beat 9.8 Jun. 30 2023 -0.34 -0.35 -0.28 Beat 19.1 This summary was machine generated August 8 at 15:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) ### Related Stocks - [ABOS.US - Acumen Pharmaceuticals](https://longbridge.com/en/quote/ABOS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 美股夜盘异动：Acumen Pharmaceuticals 夜盘涨 5.29%，资金流向明显，市场情绪引发波动性关注 | Acumen Pharmaceuticals 夜盘涨 5.29%；百济神州夜盘跌 1.71%，成交额达到 29.79 万美元；ImmunityBio 夜盘跌 0.32%，成交额达到 28.43 万美元；Moderna 夜盘跌 0.60%，成 | [Link](https://longbridge.com/en/news/273786506.md) | | 美股异动速递：美股异动：Murano Global 大涨 103.68%，坦桑尼亚皇家勘探涨 26.32% | 美股近一小时市场概况整体市场呈现出强烈的分化态势，科技股和能源股表现尤为突出。Murano Global BV 的暴涨引发了市场的广泛关注，带动了相关板块的活跃。与此同时，资金似乎更偏好于小盘股和新兴科技公司，短线热度明显上升。尽管有部分个 | [Link](https://longbridge.com/en/news/273946359.md) | | 分析 - 丰田的佐藤曾是当时的合适人选 - 然而时机发生了变化 | 丰田汽车宣布进行领导层变更，首席执行官佐藤浩二将被首席财务官近田健替换，此举是在成本压力上升和战略转向降低盈亏平衡点的背景下进行的。佐藤将担任副董事长，他的任期虽短暂，但创下了销售纪录，却因缺席关键活动而受到审视。这一变更反映了对丰田在电动 | [Link](https://longbridge.com/en/news/276404186.md) | | Acumen Pharmaceuticals 的首席法律官 Derek Meisner 报告了出售普通股的情况 | 阿库门制药公司首席法律官德里克·梅斯纳（Derek Meisner）报告了该公司普通股的出售。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供参考，不应被视为财务或法律建议。阿库门制药于 2026 年 1 月 12 日通过 E | [Link](https://longbridge.com/en/news/272332808.md) | | Acumen Pharmaceuticals 展示了其阿尔茨海默症药物研发管线中针对有毒淀粉样蛋白β寡聚体的最新进展 | Acumen Pharmaceuticals Inc. 提出了其阿尔茨海默病药物研发的进展，重点关注 Sabirnetug (ACU193)，这是一种针对有毒淀粉样β寡聚体的单克隆抗体，已获得积极的第一阶段结果，第二阶段结果预计将在 202 | [Link](https://longbridge.com/en/news/272279073.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.